Molnupiravir as a promising prodrug agent for therapy of COVID-19
https://doi.org/10.29235/1029-8940-2022-67-4-426-432
Abstract
The ongoing COVID-19 pandemic accompanied by the emergence of new successive pathogenic variants makes problematic the prospects of the approach based on application of exclusively prophylactic vaccines to combat SARSCoV-2. This reason motivated the urgent need in search and development of chemical formulas showing direct antiviral action.
The present mini-review provides data on chemical and enzymatic methods of producing molnupiravir regarded so far as one of the most effective pharmaceuticals for treatment of COVID-19. In conclusion of the literature survey it is suggested to administer lipid-containing analog instead of molnupiravir in COVID-19 therapeutic protocols. In this respect the authors reported the successful synthesis catalyzed by bacterial phospholipase D of 5′-dimyristoyl derivative of N4-hydroxycytidine – the compound allegedly more efficient than molnupiravir in inhibiting SARS-CoV-2 replication.
About the Authors
L. L. Birichevskaya
Institute of Microbiology of the National Academy of Sciences of Belarus
Belarus
Belarus
Larisa L. Birichevskaya – Ph. D (Biol.), Associate Professor, Leading Researcher
2, Kuprevich Str., 220141, Minsk
E. I. Kvasyuk
International Sakharov Environmental Institute of Belarusian State University
Belarus
Belarus
Evgeniy I. Kvasyuk – D. Sc. (Chem.), Professor
23/1, Dolgobrodskaya Str., 220070, Minsk
A. I. Zinchenko
Institute of Microbiology of the National Academy of Sciences of Belarus
Belarus
Belarus
Anatoliy I. Zinchenko – Corresponding Member, D. Sc. (Biol.), Professor, Head of the Laboratory
Review
Views:
740
Email this article 
